We are live on ! Find out more
Viking Global Investors

Viking Global Investors Portfolio holdings

AUM $35.7B
1-Year Est. Return 21.3%
This Fund
S&P 500
This Quarter Est. Return
+18.35%
1 Year Est. Return
+21.3%
3 Year Est. Return
+91.13%
5 Year Est. Return
+89.39%
10 Year Est. Return
+464.55%
AUM
$27.3B
AUM Growth
+$2.66B
Cap. Flow
-$789M
Cap. Flow %
-2.89%
Top 10 Hldgs %
40.16%
Holding
98
New
18
Increased
23
Reduced
21
Closed
19

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$955M
2
UNH icon
UnitedHealth
UNH
+$745M
3
XYZ
Block Inc
XYZ
+$545M
4
AMZN icon
Amazon
AMZN
+$536M
5
PPG icon
PPG Industries
PPG
+$416M

Sector Composition

Rank Sector Weight
1 Healthcare 28.89%
2 Financials 21.6%
3 Industrials 15.25%
4 Technology 11.5%
5 Communication Services 7.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TTWO icon
26
Take-Two Interactive
TTWO
$46.8B
$388M 1.42%
+2,412,234
New +$360M
LW icon
27
Lamb Weston
LW
$7.23B
$383M 1.4%
+3,545,376
New +$341M
MET icon
28
MetLife
MET
$61.5B
$371M 1.36%
5,616,556
+2,683,200
+91% +$168M
CBRE icon
29
CBRE Group
CBRE
$42.7B
$355M 1.3%
3,809,555
+1,304,756
+52% +$101M
DASH icon
30
DoorDash
DASH
$91.9B
$345M 1.26%
3,489,066
-1,878,456
-35% -$166M
ISRG icon
31
Intuitive Surgical
ISRG
$142B
$314M 1.15%
931,484
+290,501
+45% +$86.6M
TMO icon
32
Thermo Fisher Scientific
TMO
$224B
$286M 1.05%
538,485
-361,230
-40% -$175M
RPRX icon
33
Royalty Pharma
RPRX
$25.7B
$283M 1.04%
10,087,417
+623,216
+7% +$17.1M
INBX
34
DELISTED
Inhibrx, Inc. Common Stock
INBX
$272M 1%
7,150,826
CPNG icon
35
Coupang
CPNG
$29.7B
$251M 0.92%
15,494,869
+11,132,325
+255% +$184M
UNH icon
36
UnitedHealth
UNH
$365B
$243M 0.89%
460,782
-1,397,162
-75% -$745M
TMUS icon
37
T-Mobile US
TMUS
$192B
$242M 0.89%
+1,509,999
New +$223M
DNA icon
38
Ginkgo Bioworks
DNA
$506M
$242M 0.89%
3,577,128
EG icon
39
Everest Group
EG
$14B
$231M 0.84%
652,302
-156,157
-19% -$60.5M
ACHC icon
40
Acadia Healthcare
ACHC
$2.9B
$218M 0.8%
2,800,350
+545,137
+24% +$40.4M
FIVN icon
41
FIVE9
FIVN
$2.44B
$214M 0.78%
2,714,117
-879,628
-24% -$61.3M
HCA icon
42
HCA Healthcare
HCA
$89.1B
$196M 0.72%
+725,216
New +$179M
ADPT icon
43
Adaptive Biotechnologies
ADPT
$4.04B
$147M 0.54%
29,993,708
KBR icon
44
KBR
KBR
$4.74B
$146M 0.53%
2,633,844
+1,078,635
+69% +$59.5M
PPG icon
45
PPG Industries
PPG
$25.8B
$145M 0.53%
968,866
-3,075,378
-76% -$416M
BSX icon
46
Boston Scientific
BSX
$74.2B
$131M 0.48%
2,267,761
+1,157,469
+104% +$61.8M
CNH
47
CNH Industrial
CNH
$17.1B
$120M 0.44%
9,856,276
+3,114,995
+46% +$34.8M
VVV icon
48
Valvoline
VVV
$4.21B
$119M 0.44%
3,176,309
-5,690,854
-64% -$191M
KKR icon
49
KKR & Co
KKR
$99.6B
$115M 0.42%
+1,388,521
New +$94M
VEEV icon
50
Veeva Systems
VEEV
$38.4B
$112M 0.41%
+579,753
New +$109M

Similar funds

Viking Global Investors's Q4 2023 Portfolio in Review

As of Q4 2023, Viking Global Investors held 98 positions worth $27.3B, up 11% from $24.6B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Viking Global Investors's Q4 2023 filing shows 18 new, 23 increased, 21 reduced and 19 closed positions. Its largest new stake was Advanced Micro Devices: 4,737,399 shares worth $698M. The largest sale was Microsoft, an estimated $955M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 29% a quarter earlier, followed by Financials and Industrials.

  • Viking Global Investors's largest Q4 2023 buy was Advanced Micro Devices: 4,737,399 shares worth $698M.
  • Viking Global Investors added most to Progressive in Q4 2023, an estimated $739M increase.
  • Viking Global Investors's biggest Q4 2023 reduction was UnitedHealth, cutting an estimated $745M.
  • Viking Global Investors fully exited Microsoft in Q4 2023, selling an estimated $955M.
  • Viking Global Investors's ten largest holdings make up 40% of its $27.3B portfolio in Q4 2023.
  • Viking Global Investors opened 18 new positions and closed 19 in Q4 2023.
  • Viking Global Investors's portfolio value rose 11% quarter-over-quarter to $27.3B.

Based on Viking Global Investors's 13F filing for Q4 2023, filed 14 Feb 2024.